The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.

Eloctate is approved to help control and prevent bleeding episodes, manage bleeding during surgical procedures, and prevent or reduce the frequency of bleeding episodes (prophylaxis). Eloctate consists of the Coagulation Factor VIII molecule (historically known as Antihemophilic Factor) linked to a protein fragment, Fc, which is found in antibodies. This makes the product last longer in the patient’s blood.

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm400167.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery